ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Abstracts Of Papers Presented By Breast Cancer Task Force

August 27, 1976

NIH to ban consulting by top officials, limit outside work by other employees.

June 25, 2004

Upton Finds Work For Former Division, Program Directors

September 14, 1979

Celgene Begins Two Studies With Hoffmann-La Roche.

June 29, 2001

NCI Considers Seeking New Study Section For Clinical Research, Or Expansion Of E2

November 23, 1990

AACR Calls For Clear Statement; Says Report Was “Premature”

February 14, 1997